New hope for hard-to-treat lung cancer: targeted drug combo enters phase 2 trial
NCT ID NCT07554859
First seen May 09, 2026 · Last updated May 09, 2026
Summary
This study tests a new drug called GFH375, alone or with other medicines, in people with advanced non-small cell lung cancer that has a specific KRAS G12D mutation. About 90 participants will be split into three groups to see which treatment works best. The goal is to shrink tumors and control the disease, not to cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
Contact
Conditions
Explore the condition pages connected to this study.